P01CA129243/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2010	1
2012	2
2013	3
2014	3
2015	11
2016	1
2024	0

1

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.

Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI, Rosen N. Yao Z, et al. Cancer Cell. 2015 Sep 14;28(3):370-83. doi: 10.1016/j.ccell.2015.08.001. Epub 2015 Sep 3. Cancer Cell. 2015. PMID: 26343582 Free PMC article.

2

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Yu HA, et al. Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7. Clin Cancer Res. 2013. PMID: 23470965 Free PMC article.

3

Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.

Lovly CM. Lovly CM. Am Soc Clin Oncol Educ Book. 2015:e165-73. doi: 10.14694/EdBook_AM.2015.35.e165. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993168 Free PMC article. Review.

4

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Iams WT, Lovly CM. Iams WT, et al. Clin Cancer Res. 2015 Oct 1;21(19):4270-7. doi: 10.1158/1078-0432.CCR-14-2518. Clin Cancer Res. 2015. PMID: 26429980 Free PMC article. Review.

5

Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.

Yu HA, Riely GJ, Lovly CM. Yu HA, et al. Clin Cancer Res. 2014 Dec 1;20(23):5898-907. doi: 10.1158/1078-0432.CCR-13-2437. Epub 2014 Oct 10. Clin Cancer Res. 2014. PMID: 25303979 Free PMC article. Review.

6

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Katayama R, Lovly CM, Shaw AT. Katayama R, et al. Clin Cancer Res. 2015 May 15;21(10):2227-35. doi: 10.1158/1078-0432.CCR-14-2791. Clin Cancer Res. 2015. PMID: 25979929 Free PMC article. Review.

7

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Iams WT, Lovly CM. Iams WT, et al. Cancer J. 2015 Sep-Oct;21(5):378-82. doi: 10.1097/PPO.0000000000000142. Cancer J. 2015. PMID: 26389762 Free PMC article. Review.

8

EGFR mutant lung cancer.

Gong Y, Pao W. Gong Y, et al. Curr Top Microbiol Immunol. 2012;355:59-81. doi: 10.1007/82_2011_171. Curr Top Microbiol Immunol. 2012. PMID: 21866438

9

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

Ichihara E, Lovly CM. Ichihara E, et al. Cancer Discov. 2015 Jul;5(7):694-6. doi: 10.1158/2159-8290.CD-15-0616. Cancer Discov. 2015. PMID: 26152920 Free PMC article.

10

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Lovly CM, et al. Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667. Epub 2014 Aug 31. Nat Med. 2014. PMID: 25173427 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year